Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBITDA (2016 - 2026)

Ironwood Pharmaceuticals' EBITDA history spans 16 years, with the latest figure at -$77.0 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 344.49% to -$77.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.7 million, a 84.21% decrease, with the full-year FY2025 number at $14.7 million, down 84.21% from a year prior.
  • EBITDA hit -$77.0 million in Q4 2025 for Ironwood Pharmaceuticals, down from $75.5 million in the prior quarter.
  • Over the last five years, EBITDA for IRWD hit a ceiling of $783.9 million in Q4 2023 and a floor of -$1.1 billion in Q2 2023.
  • Historically, EBITDA has averaged $30.9 million across 5 years, with a median of $40.0 million in 2021.
  • The widest YoY moves for EBITDA: up 1504.2% in 2023, down 2964.58% in 2023.
  • Tracing IRWD's EBITDA over 5 years: stood at $41.4 million in 2021, then rose by 18.11% to $48.9 million in 2022, then soared by 1504.2% to $783.9 million in 2023, then plummeted by 95.98% to $31.5 million in 2024, then crashed by 344.49% to -$77.0 million in 2025.
  • Business Quant data shows EBITDA for IRWD at -$77.0 million in Q4 2025, $75.5 million in Q3 2025, and $45.3 million in Q2 2025.